首页> 外文期刊>Frontiers in Pharmacology >Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent
【24h】

Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent

机译:(±)-5-溴-2-(α-羟基戊基)苯甲酸钠(BZP)的临床前药代动力学,组织分布和血浆蛋白结合(BZP),一种有效的抗缺血性中风剂

获取原文
           

摘要

Sodium (±)-5-bromo-2-(α-hydroxypentyl) benzoate (BZP) is a potential cardiovascular drug and exerts potent neuroprotective effect against transient and long-term ischemic stroke in rats. BZP could convert into 3-butyl-6-bromo-1(3 H )-isobenzofuranone (Br-NBP) in vitro and in vivo . However, the pharmacokinetic profiles of BZP and Br-NBP still have not been evaluated. For the purpose of investigating the pharmacokinetic profiles, tissue distribution, and plasma protein binding of BZP and Br-NBP, a rapid, sensitive, and specific method based on liquid chromatography coupled to mass spectrometry (LC-MS/MS) has been developed for determination of BZP and Br-NBP in biological samples. The results indicated that BZP and Br-NBP showed a short elimination half-life, and pharmacokinetic profile in rats (3, 6, and 12 mg/kg; i.v. ) and beagle dogs (1, 2, and 4 mg/kg; i.v.gtt ) were obtained after single dosing of BZP. After multiple dosing of BZP, there was no significant accumulation of BZP and Br-NBP in the plasma of rats and beagle dogs. Following i.v. single dose (6 mg/kg) of BZP to rats, BZP and Br-NBP were distributed rapidly into all tissues examined, with the highest concentrations of BZP and Br-NBP in lung and kidney, respectively. The brain distribution of Br-NBP in middle cerebral artery occlusion (MCAO) rats was more than in normal rats ( P < 0.05). The plasma protein binding degree of BZP at three concentrations (8000, 20,000, and 80,000 ng/mL) from rat, beagle dog, and human plasma were 98.1–98.7, 88.9–92.7, and 74.8–83.7% respectively. In conclusion, both BZP and Br-NBP showed short half-life, good dose-linear pharmacokinetic profile, wide tissue distribution, and different degree protein binding to various species plasma. This was the first preclinical pharmacokinetic investigation of BZP and Br-NBP in both rats and beagle dogs, which provided vital guidance for further preclinical research and the subsequent clinical trials.
机译:(±)-5-溴-2-(α-羟基戊基)苯甲酸钠(BZP)是一种潜在的心血管药物,对大鼠短暂和长期缺血性中风具有有效的神经保护作用。 BZP在体外和体内均可转化为3-丁基-6-溴-1(3 H)-异苯并呋喃酮(Br-NBP)。但是,尚未评估BZP和Br-NBP的药代动力学特征。为了研究BZP和Br-NBP的药代动力学特征,组织分布和血浆蛋白结合,已开发了一种基于液相色谱-质谱联用的快速,灵敏且特异的方法(LC-MS / MS)测定生物样品中的BZP和Br-NBP。结果表明BZP和Br-NBP在大鼠(3、6和12 mg / kg; iv)和小猎犬(1、2、4和4 mg / kg; iv)中显示出较短的消除半衰期和药代动力学特征gtt)是在单剂量BZP后获得的。 BZP多次给药后,在大鼠和比格犬的血浆中没有明显的BZP和Br-NBP积聚。继i.v.对大鼠单剂量(6 mg / kg)的BZP,BZP和Br-NBP迅速分布到所有检查的组织中,肺和肾脏中BZP和Br-NBP的浓度最高。 Br-NBP在大脑中动脉闭塞(MCAO)大鼠中的脑分布大于正常大鼠(P <0.05)。来自大鼠,比格犬和人血浆的三种浓度(8000、20,000和80,000 ng / mL)的BZP血浆蛋白结合度分别为98.1–98.7、88.9–92.7和74.8–83.7%。总之,BZP和Br-NBP均显示出短的半衰期,良好的剂量线性药代动力学特征,较宽的组织分布以及与各种物种血浆的不同程度的蛋白质结合。这是BZP和Br-NBP在大鼠和比格犬中的首次临床前药代动力学研究,为进一步的临床前研究和后续临床试验提供了重要的指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号